Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07977317
ABSTRACT:
This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
REFERENCES:
patent: 4018884 (1977-04-01), Cleeland, Jr. et al.
patent: 4391904 (1983-07-01), Litman et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4715359 (1987-12-01), Ryo
patent: 4744981 (1988-05-01), Pavanasasivam
patent: 4832686 (1989-05-01), Anderson
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5106951 (1992-04-01), Morgan, Jr. et al.
patent: 5186941 (1993-02-01), Callahan et al.
patent: 5256413 (1993-10-01), Haber et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5474766 (1995-12-01), Schwartz et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5525735 (1996-06-01), Gallop et al.
patent: 5541061 (1996-07-01), Fodor et al.
patent: 5549974 (1996-08-01), Holmes
patent: 5559410 (1996-09-01), Papazian et al.
patent: 5576220 (1996-11-01), Hudson et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5650391 (1997-07-01), Schwartz et al.
patent: 5672683 (1997-09-01), Friden et al.
patent: 5962012 (1999-10-01), Lin et al.
patent: 5962266 (1999-10-01), White et al.
patent: 5977435 (1999-11-01), Lefebvre et al.
patent: 5981194 (1999-11-01), Jefferies et al.
patent: 5994127 (1999-11-01), Selden et al.
patent: 6048729 (2000-04-01), Selden et al.
patent: 6063630 (2000-05-01), Treco et al.
patent: 6072041 (2000-06-01), Davis et al.
patent: 6090925 (2000-07-01), Woiszwillo et al.
patent: 6156311 (2000-12-01), Strickland et al.
patent: 6165476 (2000-12-01), Strom et al.
patent: 6261595 (2001-07-01), Stanley et al.
patent: 6331611 (2001-12-01), Murgita
patent: 6372712 (2002-04-01), Briesewitz et al.
patent: 6432412 (2002-08-01), Emery et al.
patent: 6447775 (2002-09-01), Strickland et al.
patent: 6455494 (2002-09-01), Jeffries et al.
patent: 6743427 (2004-06-01), Schenk
patent: 7560431 (2009-07-01), Zankel et al.
patent: 7569544 (2009-08-01), Zankel et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2003/0129186 (2003-07-01), Beliveau et al.
patent: 2003/0215440 (2003-11-01), Gruber et al.
patent: WO-88/04690 (1988-06-01), None
patent: WO-00/04926 (2000-02-01), None
patent: WO-00/71714 (2000-11-01), None
patent: WO-01/59459 (2001-08-01), None
patent: WO-02/13843 (2002-02-01), None
patent: WO-03/009815 (2003-02-01), None
Czekay 1997 Molecular Biology of the Cell 8:517-532.
Platt 1998 Biochemical Pharmacology 56:421-430.
Albeck, A non-invasive transport system for GDNF across the blood-brain barrierNeuroreport, 8:2293-8 (1997).
Alemany et al., Glycosyl Phosphatidylinositol Membrane Anchoring of Melanotransferrin (p97): Apical Compartmentalization in Intestinal Epithelial Cells,J. Cell Sci., 104:1155-62 (1993).
Altschul et al., Basic Local Alignment Search Tool,J. Mol. Biol., 215(3):403-10 (1990).
Anderson et al., Differential Binding of Ligands to the Apolipoprotein E Receptor 2,Biochemistry, 42:9355-64 (2003).
Anderson et al., Dominant Thermodynamic Role of the Third Independent Receptor Binding Site in the Receptor-Associated Protein RAP,Biochemistry, 40:15408-15417 (2001).
Anderson et al., Identification of the Minimal Functional Unit in the Low Density Lipoprotein Receptor-related Protein for Binding the Receptor-associated Protein (RAP),J. Biol. Chem., 275(28):21017-21024 (2000).
Ashcom et al., The Human α2-Macroglobulin Receptor: Identification of a 420-kD Cell Surface Glycoprotein Specific for the Activated Conformation of α2-Macroglobulin,J. Cell. Biol., 110(4):1041-1048 (1990).
Bajari et al., A Minimal Binding Domain of the Low Density Lipoprotein Receptor Family,Biol. Chem., 379:1053-1062 (1998).
Baker et al., Human melanotransferrin (p97) has only one functional iron-binding site,FEBS Lett., 298(2-3):215-218 (1992).
Bickel et al., Delivery of Peptides and Proteins Through the Blood-brain Barrier,Adv. Drug Deliv. Rev., 46(1-3):247-79 (2001).
Bickel et al., Pharmacologic Effects in Vivo in Brain by Vector-mediated Peptide Drug Delivery,Proc. Nalt. Acad. Sci.(USA), 90:2618-2622 (1993).
Biotech Week, p. 3 (2002).
Blair et al., Linkage of Cytotoxic Agents to Immunoglobulins,J. Immunol. Methods, 59(2):129-143 (1983).
Blattler et al., New Heterobifunctional Protein Cross-linking Reagent that Forms an Acid-labile Link,Biochem., 24:1517-1524 (1985).
Bogan et al., Anatomy of Hot Spots in Protein Interfaces,J. Mol. Biol., 280:1-9 (1998).
Brown et al., Human melanoma-associated antigen p97 is structurally and functionally related to transferrin,Nature, 296(5853):171-173 (1982).
Brown et al., Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues,Proc. Natl. Acad. Sci.(USA), 78(1):539-543 (1981).
Bu et al., RAP, a Novel Type of ER Chaperone,Trends Cell Biol., 8(7):272-276 (1998).
Bu et al., Receptor-associated Protein is a Folding Chaperone for Low Density Lipoprotein Receptor-related Protein,J. Biol. Chem., 271(36):22218-22224 (1996).
Bu et al., Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells,J. Biol. Chem., 268(17):13002-13009 (1993).
Bu, The Roles of Receptor-Associated Protein (RAP) as a Molecular Chaperone for Members of the LDL Receptor Family,Int. Rev. Cytol., 209:79-116 (2001).
Canals et al., Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Asociated with Enkephalinergic Neuronal Degeneration in Huntington's Disease,J. Neuroscience, 24(35):7727-39 (2004).
Cecchelli et al., In vitro model for evaluating drug transport across the blood-brain barrier,Adv. Drug Deliv. Rev., 36(2-3):165-78 (1999).
Cho et al., An unnatural biopolymer,Science, 261(5126):1303-5 (1993).
Clackson et al., A Hot Spot of Binding Energy in a Hormone-receptor Interface,Science, 267:383-386 (1995).
Cook et al., Serum transferrin receptor,Annu. Rev. Med., 44:63-74 (1993).
Czekay et al., Endocytic Trafficking of Megalin/RAP Complexes: Dissociation of the Complexes in Late Endosomes,Mol. Biol. Cell., 8(3):517-32 (1997).
Dagenais et al., Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice,J. Cereb. Blood Flow Metab., 20(2):381-6 (2000).
Dallaire et al., Phosphate transport by capillaries of the blood-brain barrier,J. Biol. Chem., 267(31):22323-7 (1992).
Dallaire et al., Purification and Characterization of Metabolically Active Capillaries of the Blood-brain Barrier,Biochem. J., 276(Pt.3):745-52 (1991).
Dehouck et al., A New Function for the LDL Receptor: Transcytosis of LDL Across the Blood-brain Barrier,J. Cell Biol., 138(4):877-889 (1997).
Dehouck et al., Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models,J. Neurochem., 58(5):1790-1797 (1992).
Dehouck et al., Drug transport to the brain: comparison between in vitro and in vivo models of the blood-brain barrier,Eur. J. Pharm. Sci., 3:357-65 (1995).
Dehouck et al., In vitro reconstituted blood-brain barrier,J. Controlled Release, 21:81-91 (1992).
DeLano et al., Unraveling Hot Spots in Binding Interfaces Progress and Challenges,Curr. Opin. Struct. Biol., 12:14-20 (2002).
Demeule et al., Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors,Int. J. Cancer, 93(1):62-66 (2001).
Descamps et al., Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells,Am. J. Physiol., 270(4 Pt.2):H1149-H1158 (1996).
Dwyer et al., Hight Affinity RNase S-Peptide Variants Obtained by Phage Display Have a Novel ‘Hot-Spot’ of Binding Energy,Biochemistry, 40:13491-13500
Beliveau Richard
Demeule Michel
Gabathuler Reinhard
Kennard Malcolm L.
Yang Joseph
Kolker Daniel E
Marshall & Gerstein & Borun LLP
Raptor Pharmaceutical Inc.
LandOfFree
Compositions and methods for modulating blood-brain barrier... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulating blood-brain barrier..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulating blood-brain barrier... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668137